Bruce Binkowitz

Corporate Officer/Principal bei ARCUTIS BIOTHERAPEUTICS, INC.

Health Technology

Consumer Services

Aktive Positionen von Bruce Binkowitz

Unternehmen	Position	Beginn	Ende
ARCUTIS BIOTHERAPEUTICS, INC.	Corporate Officer/Principal	23.08.2021	-

Unternehmen	Position	Beginn	Ende
Shionogi, Inc. Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.	Corporate Officer/Principal	-	-

University of Florida	Graduate Degree
Rutgers School of Public Health	Doctorate Degree

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	2
Graduate Degree	1
Doctorate Degree	1

Sektoral

Health Technology	3
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
ARCUTIS BIOTHERAPEUTICS, INC.	Health Technology

Private Unternehmen	1
Shionogi, Inc. Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.	Health Technology

Private Unternehmen

Health Technology